Compare
BioXcel Therapeutics, Inc. vs Vaccinex, Inc. vs PMGC Holdings Inc. vs Lexaria Bioscience Corp.
| Latest fiscal year | BioXcel Therapeutics, Inc. BTAIQ | Vaccinex, Inc. VCNXLast annual report: year ended 2024-12-31 | PMGC Holdings Inc. ELAB | Lexaria Bioscience Corp. LEXX |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2024-12-31 | 2025-12-31 | 2025-08-31 |
| Revenue | $642.0K | $601.0K | $590.1K | $705.9K |
| Revenue growth (YoY) | -71.7% | +5.4% | n/a | +52.0% |
| Gross margin | 74.5% (computed) | n/a | 31.4% | 99.6% |
| Operating margin | n/m | n/m | n/a | n/m |
| Net margin | n/m | n/m | n/m | n/m |
| Net income | -$69.90M | -$18.63M | -$7.75M | -$11.90M |
| EPS (Diluted) | -$5.73 | -$8.88 | n/a | -$0.66 |
| Operating cash flow | -$57.62M | -$16.19M | -$5.93M | -$10.45M |
| Free cash flow | -$57.62M | -$16.21M | -$6.38M | -$10.48M |
| Cash & equivalents | $28.41M | $1.11M | n/a | n/a |
| Total assets | $44.92M | $2.60M | $12.87M | $4.18M |
| Total liabilities | $140.38M | $5.08M | $5.03M | $1.57M |
| Shareholders' equity | -$95.46M | -$2.49M | $7.84M | $2.99M |
| Return on year-end equity | n/a | n/a | -98.9% | -398.1% |
| Shares outstanding | 22.33M | 2.68M | 80.7K | 19.56M |
Revenue, most recent five fiscal years
| Fiscal year | BioXcel Therapeutics, Inc. | Vaccinex, Inc. | PMGC Holdings Inc. | Lexaria Bioscience Corp. |
|---|---|---|---|---|
| Latest | $642.0K Ended 2025-12-31 | $601.0K Ended 2024-12-31 | $590.1K Ended 2025-12-31 | $705.9K Ended 2025-08-31 |
| 1 year earlier | $2.27M Ended 2024-12-31 | $570.0K Ended 2023-12-31 | n/a | $464.3K Ended 2024-08-31 |
| 2 years earlier | $1.38M Ended 2023-12-31 | $275.0K Ended 2022-12-31 | $1.71M Ended 2023-12-31 | $226.2K Ended 2023-08-31 |
| 3 years earlier | $375.0K Ended 2022-12-31 | $900.0K Ended 2021-12-31 | $766.3K Ended 2022-12-31 | $255.4K Ended 2022-08-31 |
| 4 years earlier | n/a | $625.0K Ended 2020-12-31 | n/a | $722.7K Ended 2021-08-31 |